Kendle Appoints Philip J.W. Davies Vice President, Phase I
Position to drive global business strategy required for successful delivery of early stage clinical trials.
Cincinnati, OH-January 14, 2008—Kendle (www.kendle.com), a leading, global full-service clinical research organization (CRO), today announced the appointment of Philip J.W. Davies to the position of vice president, Phase I. Davies will provide global leadership to strengthen and grow the company’s Phase I business which includes a clinical pharmacology unit in The Netherlands and a bioequivalence unit in West Virginia, and will focus on expanding Phase I capabilities globally. Davies will be based in Kendle’s Cincinnati headquarters and will report directly to Candace Kendle, chairman and chief executive officer.
“Phase I is a rapidly growing area of opportunity and is an integral part of Kendle’s business plan, with the market expected to grow between 13.4 and 16 percent annually through 2010,” said Kendle. “I am pleased to welcome Phil to this key leadership role as Kendle focuses on the strategic expansion of our early stage capabilities to meet our customers’ needs.”
Davies brings more than two decades of pharmacology expertise to this position. He joins Kendle from Eli Lilly and Company where he served most recently as director of global exploratory and program phase medical operations. He has been with Eli Lilly since 2001, serving in multiple roles of increasing responsibility, including director, global exploratory medicine operations; director, global clinical pharmacology operations; and director, U.S. clinical pharmacology operations. Prior to Eli Lilly, Davies served as director of Kendle’s clinical pharmacology unit in The Netherlands and previously held clinical pharmacology roles in Germany and the UK.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
